SCHEMBL23748151

SCHEMBL23748151

C=CCOc1ccccc1C(O)c1cccnc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.52
SMN1; SMN2 Q16637 3/20 0.49
LMNA P02545 3/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
POLB P06746 1/20 0.41
SLC6A4 P31645 3/20 0.40
TSHR P16473 2/20 0.40
SLC22A1 O15245 1/20 0.40
CYP1A2 P05177 1/20 0.40
ADRB2 P07550 1/20 0.40
ADRB1 P08588 1/20 0.40
HTR1A P08908 1/20 0.40
CYP2D6 P10635 1/20 0.40
HTR2A P28223 1/20 0.40
ADRA1A P35348 1/20 0.40
DRD2 P14416 1/20 0.40
DRD1 P21728 1/20 0.40
HPGD P15428 1/20 0.40
MAPK1 P28482 1/20 0.40
HSD17B10 Q99714 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23748235 0.84 DRD2 (0.52) GAALMNASLC6A4TSHRSLC22A1
SCHEMBL24354129 0.84 POLB (0.41) GAASMN1; SMN2LMNAPOLBSLC6A4
SCHEMBL24834940 0.83 SMN1; SMN2 (0.43) GAASMN1; SMN2LMNAPOLBSLC6A4
SCHEMBL10966577 0.80 GAA (0.50) GAASMN1; SMN2LMNAL3MBTL1SLC6A4
SCHEMBL25262647 0.79 GAA (0.67) GAASMN1; SMN2LMNAL3MBTL1SLC6A4
SCHEMBL24354150 0.78 HPGD (0.43) LMNAL3MBTL1SLC6A4TSHRSLC22A1
SCHEMBL11187897 0.78 GAA (0.48) GAASMN1; SMN2LMNAL3MBTL1SLC6A4
SCHEMBL10967138 0.78 GAA (0.48) GAASMN1; SMN2LMNAL3MBTL1SLC6A4
SCHEMBL23748213 0.77 LIG1 (0.43) GAASMN1; SMN2LMNAL3MBTL1SLC6A4
SCHEMBL29854023 0.77 SMN1; SMN2 (0.42) GAASMN1; SMN2LMNAL3MBTL1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230002409-A1 MACROCYCLIC FLU ENDONUCLEASE INHIBITORS JANSSEN BIOPHARMA INC (US) 2023-01-05 US disclosed
US-20230002409-A1 MACROCYCLIC FLU ENDONUCLEASE INHIBITORS JANSSEN BIOPHARMA INC (US) 2023-01-05 US disclosed
US-11312727-B1 Macrocyclic flu endonuclease inhibitors Janssen Biopharma, Inc. (US) 2022-04-26 US disclosed
US-11312727-B1 Macrocyclic flu endonuclease inhibitors Janssen Biopharma, Inc. (US) 2022-04-26 US disclosed
EP-3864020-A1 MACROCYCLIC FLU ENDONUCLEASE INHIBITORS Janssen BioPharma, Inc. (US) 2021-08-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230002409-A1 MACROCYCLIC FLU ENDONUCLEASE INHIBITORS ACE, PNP, FEN1 GAA 225/4885SMN1; SMN2 3508/4885LMNA 1057/4885
US-11312727-B1 Macrocyclic flu endonuclease inhibitors ACE, FEN1, PNP GAA 200/4885SMN1; SMN2 3520/4885LMNA 965/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.